Development and Commercialization License and Assignment. Adimab hereby, effective on Surface’s exercise of the Commercial Option for a Target and the applicable Licensed Antibodies:
Appears in 4 contracts
Samples: Development and Option Agreement (Coherus BioSciences, Inc.), Development and Option Agreement (Surface Oncology, Inc.), Development and Option Agreement (Surface Oncology, Inc.)